scholarly journals PATH-55. THE POTENTIAL ROLE OF ERCC1 AS A BIOMARKER FOR PLATINUM BASED THERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi183-vi183
Author(s):  
Lyndon Kim ◽  
Kevin Judy ◽  
Christopher Farrell ◽  
James Evans ◽  
David Andrews
Keyword(s):  
Brain Tumors ◽  
Potential Role ◽  
Metastatic Brain Tumors

scholarly journals Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors

2020 ◽  
Vol 21 (11) ◽  
pp. 3849 ◽  
Author(s):  
Andrea Cimini ◽  
Maria Ricci ◽  
Agostino Chiaravalloti ◽  
Luca Filippi ◽  
Orazio Schillaci
Keyword(s):  
Nuclear Medicine ◽  
Brain Tumors ◽  
Pediatric Oncology ◽  
Potential Role ◽  
Pediatric Tumors ◽  
Web Based ◽  
Literature Research ◽  
Preliminary Results ◽  
Personal Approach

The use of theragnostic radiopharmaceuticals in nuclear medicine has grown rapidly over the years to combine the diagnosis and therapy of tumors. In this review, we performed web-based and desktop literature research to investigate and explain the potential role of theragnostic imaging in pediatric oncology. We focused primarily on patients with aggressive malignancies such as neuroblastoma and brain tumors, to select patients with the highest chance of benefit from personalized therapy. Moreover, the most critical and groundbreaking applications of radioimmunotherapy in children’s oncology were examined in this peculiar context. Preliminary results showed the potential feasibility of theragnostic imaging and radioimmunotherapy in pediatric oncology. They revealed advantages in the management of the disease, thereby allowing an intra-personal approach and adding new weapons to conventional therapies.

scholarly journals EPT-11THE POTENTIAL ROLE OF REGADENOSON TO TRANSIENTLY DISRUPT THE BLOOD-BRAIN BARRIER AND IMPROVE TEMOZOLOMIDE DELIVERY TO BRAIN TUMORS

2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii26.1-iii26
Author(s):  
Sadhana Jackson ◽  
Anna Piotrowski ◽  
Jon Weingart ◽  
Thura Abd ◽  
Richard George ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Blood Brain Barrier ◽  
Potential Role ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals The Role of Stereotactic Cyst Aspiration for Glial and Metastatic Brain Tumors

2000 ◽  
Vol 27 (3) ◽  
pp. 229-235 ◽  
Author(s):  
Ajay Niranjan ◽  
Timothy Witham ◽  
Douglas Kondziolka ◽  
L. Dade Lunsford
Keyword(s):  
Brain Tumors ◽  
Tumor Volume ◽  
Gamma Knife Radiosurgery ◽  
Symptomatic Improvement ◽  
Resonance Imaging ◽  
Metastatic Brain Tumors ◽  
Metastatic Tumors ◽  
Stereotactic Aspiration ◽  
Cyst Aspiration

Objective:To evaluate the role of stereotactic cyst aspiration in the context of multimodality management of cystic glial and metastatic tumors, we retrospectively reviewed our experience with 38 patients during a 10-year interval.Methods:All 38 patients had one or more computed tomography or magnetic resonance imaging guided stereotactic cyst aspirations. Twenty-seven patients had glial neoplasms and 11 had metastatic brain tumors. Twenty-two patients underwent cyst aspiration as the initial treatment modality while 15 patients had cyst aspiration following previous treatments.Results:In the immediate postoperative period, 19 of the 27 (70%) patients with gliomas and nine of the 11 (82%) patients with metastatic tumors experienced symptomatic improvement. No procedure-related morbidity was encountered. Twelve patients (31.5%) eventually required a catheter-reservoir system. Thirty-seven percent of patients with cystic glial neoplasms and 18% of patients with metastatic tumors had delayed cytoreductive surgery by craniotomy subsequent to stereotactic cyst aspiration. Reduction in tumor volume following aspiration facilitated Gamma knife radiosurgery in seven patients.Conclusion:Single stereotactic aspiration is a low risk procedure that provides immediate relief of symptoms in patients with cystic brain tumors. It appears to be valuable together with the use of other therapeutic strategies.

Brain tumors: Regulation of angiogenesis.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13540-e13540 ◽  
Author(s):  
Eduard Evgenevich Rostorguev ◽  
Elena Mikhaylovna Frantsiyants ◽  
Yulia A. Pogorelova ◽  
Natalia D. Cheryarina ◽  
Larisa Kozlova ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Test Results ◽  
Metastatic Brain Tumors ◽  
Metastatic Tissue ◽  
Pathological Angiogenesis ◽  
Important Mediator ◽  
Student’S T ◽  
G 14 ◽  
Student’S T Test

e13540 Background: Cancer implicates pathological angiogenesis. The problem of treatment for primary and metastatic brain tumors is still unsolved. In addition to main angiogenic functions, VEGF family performs important mediator functions in the immune system. The role of VEGF family in central nervous system tumors is poorly studied. Our purpose was to study the levels of factors of angio- and lymphangiogenesis in tissues of glioblastomas (G), brain metastases (MTS), meningiomas and corresponding peritumoral area. Methods: Tissues of tumor and peritumoral zone (PZ) obtained during the surgery from 22 patients with G, 14 patients with brain MTS from breast cancer and 12 meningioma patients, mean age 39.2±4.8 years, were studied. Levels of VEGF-A, VEGFR-1, VEGF-C and VEGFR-3 were determined by ELISA. The data were processed using Statistica 10 program. The significance of differences was determined by Student's t-test. Results: VEGF-A levels in tissues of G and MTS were higher than in meningioma tissues by 74.7 and 94.5 times, respectively; levels of VEGF-R1 were 2.7 and 3.9 higher, and the VEGF-A/VEGF-R1 coefficient was 28.1 and 24.1 times higher, respectively. Levels of VEGF-C and VEGF-R3 were escalated only in G tissues compared to meningiomas (by 1.7 times on average). The VEGF-С/VEGF-R3 coefficient was similar in all studied tumors. VEGF-A levels were higher in PZ of G and MTS compared to PZ of meningiomas – by 78.2 and 110.7 times, respectively, while VEGF-R1 level was higher in G PZ only (by 5.5 times). The VEGF-A/VEGF-R1 coefficient was 14.5 and 128.5 times higher, respectively. VEGF-C level in PZ of G was escalated compared to meningiomas by 6.5 times, in MTS – by 1.6 times. VEGFR-3 contents did not differ significantly in all PZ samples, but the VEGF-С/VEGF-R3 coefficient was higher in PZ in G by 9 times and in MTS by 2 times. Conclusions: Compared to benign meningiomas, angio- and lymphangiogenesis are activated in glioblastoma tissue and angiogenesis – in metastatic tissue. Lymphangiogenesis is more active in peritumoral zone of glioblastomas compared to metastatic tissue, and angiogenesis is more active in peritumoral zone of metastases.

Guidelines for the Initial Management of Metastatic Brain Tumors: Role of Surgery, Radiosurgery, and Radiation Therapy

2008 ◽  
Vol 6 (5) ◽  
pp. 505-514 ◽  
Author(s):  
Matthew G. Ewend ◽  
David E. Morris ◽  
Lisa A. Carey ◽  
Alim M. Ladha ◽  
Steven Brem
Keyword(s):  
Radiation Therapy ◽  
Brain Tumors ◽  
Metastatic Brain Tumors ◽  
Initial Management

scholarly journals Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors

Neurosurgery ◽  
2019 ◽  
Vol 84 (3) ◽  
pp. E152-E155 ◽  
Author(s):  
Brian V Nahed ◽  
Christopher Alvarez-Breckenridge ◽  
Priscilla K Brastianos ◽  
Helen Shih ◽  
Andrew Sloan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Brain Tumors ◽  
Evidence Based ◽  
Metastatic Brain Tumors ◽  
Evidence Based Guidelines

scholarly journals Therapeutically Significant MicroRNAs in Primary and Metastatic Brain Malignancies

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2534 ◽  
Author(s):  
Akilandeswari A. Balachandran ◽  
Leon M. Larcher ◽  
Suxiang Chen ◽  
Rakesh N. Veedu
Keyword(s):  
Brain Tumors ◽  
High Mortality ◽  
Survival Rates ◽  
Primary Brain Tumor ◽  
Metastatic Brain Tumors ◽  
Poor Survival ◽  
Aggressive Form ◽  
Targeted Treatments ◽  
The Given

Brain cancer is one among the rare cancers with high mortality rate that affects both children and adults. The most aggressive form of primary brain tumor is glioblastoma. Secondary brain tumors most commonly metastasize from primary cancers of lung, breast, or melanoma. The five-year survival of primary and secondary brain tumors is 34% and 2.4%, respectively. Owing to poor prognosis, tumor heterogeneity, increased tumor relapse, and resistance to therapies, brain cancers have high mortality and poor survival rates compared to other cancers. Early diagnosis, effective targeted treatments, and improved prognosis have the potential to increase the survival rate of patients with primary and secondary brain malignancies. MicroRNAs (miRNAs) are short noncoding RNAs of approximately 18–22 nucleotides that play a significant role in the regulation of multiple genes. With growing interest in the development of miRNA-based therapeutics, it is crucial to understand the differential role of these miRNAs in the given cancer scenario. This review focuses on the differential expression of ten miRNAs (miR-145, miR-31, miR-451, miR-19a, miR-143, miR-125b, miR-328, miR-210, miR-146a, and miR-126) in glioblastoma and brain metastasis. These miRNAs are highly dysregulated in both primary and metastatic brain tumors, which necessitates a better understanding of their role in these cancers. In the context of the tumor microenvironment and the expression of different genes, these miRNAs possess both oncogenic and/or tumor-suppressive roles within the same cancer.

Sign in / Sign up

Export Citation Format

Share Document